GM-CSF Targeted Therapies – Target Pipeline List 04/2019

Targets: GM-CSF; granulocyte macrophage-colony stimulating factor; GM-CSF receptor; GM-CSF-R

This Target Pipeline List provides an overview of therapeutic antibodies against GM-CSF or its receptor in development for treatment of inflammatory diseases.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a type of protein that plays a central role in a broad range of immune mediated diseases, including rheumatoid arthritis.  It activates cells, including macrophages, leading to inflammation and joint damage. Neutralising the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor is a promising novel pharmacologic strategy for treatment of inflammatory diseases.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.